ResearcherNational Taiwan UniversityNo recent work listed
Min‐Chuan Huang
Matched on ORCID iD 0000-0002-0704-3447; OpenAlex author ID A5073677542. Sources: OpenAlex.
Their work
- Papers
- 2 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 4
2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper
Papers 2
- C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin αv. Last author DOI 10.1038/s41388-020-01594-4↗
- Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Last author DOI 10.1038/s41388-018-0403-0↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yu‐Wen Tien · 2 shared papers, 2018–2021 · strength 0.23
- Paper C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes… DOI 10.1038/s41388-020-01594-4↗
- Paper Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of t… DOI 10.1038/s41388-018-0403-0↗
- Ting‐Chun Kuo · 2 shared papers, 2018–2021 · strength 0.23
- Paper C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes… DOI 10.1038/s41388-020-01594-4↗
- Paper Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of t… DOI 10.1038/s41388-018-0403-0↗
- Syue‐Ting Chen · 2 shared papers, 2018–2021 · strength 0.23
- Paper C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes… DOI 10.1038/s41388-020-01594-4↗
- Paper Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of t… DOI 10.1038/s41388-018-0403-0↗
- Shih‐Hung Yang · 1 shared paper, 2021 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.